

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Reqsted: 06/14/2006
Time Report Reqsted: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

C Number: C20201B
Lock Date: 07/24/2004
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	360 NG/KG	1210 NG/KG	3600 NG/KG	7600 NG/KG
Disposition Summary					
Animals Initially in Study	20	20	20	20	20
Early Deaths					
Moribund Sacrifice	1	3	3	2	1
Natural Death	2	3	5	2	1
Survivors					
Natural Death		1			
Terminal Sacrifice	17	13	12	16	18
Animals Examined Microscopically	20	20	20	20	20
ALIMENTARY SYSTEM					
Gallbladder	(0)	(0)	(1)	(0)	(0)
Inflammation, Granulomatous			1 (100%)		
Liver	(20)	(20)	(20)	(20)	(20)
Clear Cell Focus	1 (5%)				
Fatty Change	1 (5%)	2 (10%)	2 (10%)	1 (5%)	2 (10%)
Hematopoietic Cell Proliferation	1 (5%)	1 (5%)	1 (5%)	2 (10%)	10 (50%)
Hepatodiaphragmatic Nodule	1 (5%)				
Inflammation	19 (95%)	17 (85%)	14 (70%)	18 (90%)	19 (95%)
Necrosis	7 (35%)	8 (40%)	6 (30%)	6 (30%)	13 (65%)
Pigmentation	10 (50%)	8 (40%)	10 (50%)	14 (70%)	10 (50%)
Mesentery	(1)	(0)	(0)	(2)	(0)
Artery, Thrombosis				1 (50%)	
Fat, Necrosis	1 (100%)			1 (50%)	
Pancreas	(0)	(0)	(0)	(1)	(0)
Necrosis				1 (100%)	
Artery, Inflammation, Chronic Active				1 (100%)	
Salivary Glands	(1)	(0)	(0)	(0)	(1)
Stomach, Forestomach	(6)	(3)	(2)	(7)	(7)
Stomach, Glandular	(1)	(0)	(0)	(0)	(0)
Glands, Hyperplasia	1 (100%)				
Tooth	(6)	(3)	(6)	(2)	(4)

CARDIOVASCULAR SYSTEM

None

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	360 NG/KG	1210 NG/KG	3600 NG/KG	7600 NG/KG
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
Ovary	(1)	(1)	(0)	(0)	(0)
Uterus	(0)	(0)	(0)	(1)	(0)
Atrophy				1 (100%)	
HEMATOPOIETIC SYSTEM					
Lymph Node	(0)	(1)	(0)	(0)	(0)
Lymph Node, Mandibular	(0)	(3)	(0)	(0)	(1)
Hyperplasia, Plasma Cell		2 (67%)			1 (100%)
Lymph Node, Mesenteric	(1)	(1)	(0)	(0)	(0)
Spleen	(20)	(20)	(20)	(20)	(20)
Hematopoietic Cell Proliferation	3 (15%)		5 (25%)	10 (50%)	17 (85%)
Necrosis				1 (5%)	
Thymus	(20)	(19)	(19)	(20)	(20)
Atrophy	3 (15%)	1 (5%)	7 (37%)	2 (10%)	7 (35%)
INTEGUMENTARY SYSTEM					
Skin	(4)	(5)	(5)	(5)	(6)
Fibrosis	1 (25%)		2 (40%)		
Hyperplasia, Squamous	4 (100%)	2 (40%)	1 (20%)		4 (67%)
Inflammation, Chronic Active	3 (75%)	2 (40%)	2 (40%)	1 (20%)	2 (33%)
Ulcer	1 (25%)				1 (17%)
Skin, Control Dermis	(20)	(20)	(20)	(20)	(20)
Inflammation, Chronic Active		2 (10%)			1 (5%)
Skin, Control Epidermis	(20)	(20)	(20)	(20)	(20)
Hyperplasia, Squamous		2 (10%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	360 NG/KG	1210 NG/KG	3600 NG/KG	7600 NG/KG
Skin, Site Of Application	(20)	(20)	(20)	(20)	(20)
Fibrosis	1 (5%)				
Hyperplasia, Mast Cell					1 (5%)
Hyperplasia, Squamous	1 (5%)		3 (15%)	8 (40%)	14 (70%)
Inflammation, Chronic Active	2 (10%)		6 (30%)	18 (90%)	20 (100%)
Ulcer			1 (5%)		2 (10%)
Skin, Soa No Mass	(20)	(20)	(20)	(19)	(16)
Hyperplasia, Squamous	1 (5%)	3 (15%)		3 (16%)	6 (38%)
Inflammation, Chronic Active	3 (15%)	4 (20%)	2 (10%)	8 (42%)	11 (69%)
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
Brain	(0)	(0)	(1)	(0)	(0)
Meninges, Hemorrhage			1 (100%)		
RESPIRATORY SYSTEM					
Lung	(20)	(20)	(20)	(20)	(20)
Alveolar Epithelium, Hyperplasia		1 (5%)	1 (5%)		
Alveolus, Infiltration Cellular, Histocyte		1 (5%)			1 (5%)
Bronchiole, Inflammation					1 (5%)
Interstitial, Inflammation	1 (5%)			1 (5%)	3 (15%)
Perivascular, Inflammation	2 (10%)			1 (5%)	2 (10%)
Serosa, Inflammation, Chronic Active	7 (35%)				1 (5%)
SPECIAL SENSES SYSTEM					
Eye	(0)	(0)	(1)	(0)	(0)
Anterior Chamber, Cornea, Inflammation, Suppurative			1 (100%)		
URINARY SYSTEM					
Kidney	(0)	(0)	(1)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Reqsted: 06/14/2006
Time Report Reqsted: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	360 NG/KG	1210 NG/KG	3600 NG/KG	7600 NG/KG

*** END OF REPORT ***